CL2016000530A1 - Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13). - Google Patents

Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).

Info

Publication number
CL2016000530A1
CL2016000530A1 CL2016000530A CL2016000530A CL2016000530A1 CL 2016000530 A1 CL2016000530 A1 CL 2016000530A1 CL 2016000530 A CL2016000530 A CL 2016000530A CL 2016000530 A CL2016000530 A CL 2016000530A CL 2016000530 A1 CL2016000530 A1 CL 2016000530A1
Authority
CL
Chile
Prior art keywords
osteoarthritis
pain
divisional
sun
treatment
Prior art date
Application number
CL2016000530A
Other languages
English (en)
Inventor
Rajesh V Kamath
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2016000530A1 publication Critical patent/CL2016000530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

USO DE PROTEÍNA DE UNIÓN A IL-1alfa Y PROTEÍNA DE UNIÓN A IL-1beta O PROTEÍNA DE UNIÓN A AMBAS PARA LA FABRICACIÓN DE UN MEDICAMENTO PARA TRATAR EL DOLOR Y LA OSTEOARTRITIS; Y COMPOSICIÓN (DIVISIONAL DE SOL. N°2298-13).
CL2016000530A 2011-02-08 2016-03-08 Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13). CL2016000530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161440853P 2011-02-08 2011-02-08

Publications (1)

Publication Number Publication Date
CL2016000530A1 true CL2016000530A1 (es) 2016-12-02

Family

ID=46600758

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002298A CL2013002298A1 (es) 2011-02-08 2013-08-07 Uso de una proteina de union con un dominio variable dual de inmunoglobulina (dvd-ig) que se une a il-1 alfa e il-1 beta para preparar un medicamento util para el tratamiento de la osteoartritis
CL2016000530A CL2016000530A1 (es) 2011-02-08 2016-03-08 Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013002298A CL2013002298A1 (es) 2011-02-08 2013-08-07 Uso de una proteina de union con un dominio variable dual de inmunoglobulina (dvd-ig) que se une a il-1 alfa e il-1 beta para preparar un medicamento util para el tratamiento de la osteoartritis

Country Status (18)

Country Link
US (2) US8889130B2 (es)
EP (1) EP2672997A4 (es)
JP (2) JP5918275B2 (es)
KR (2) KR20150080033A (es)
CN (2) CN105749286A (es)
AU (2) AU2012214449B2 (es)
BR (1) BR112013020259A2 (es)
CA (1) CA2826564C (es)
CL (2) CL2013002298A1 (es)
CO (1) CO6751274A2 (es)
DO (2) DOP2013000178A (es)
IL (1) IL227771A0 (es)
MX (1) MX341578B (es)
RU (2) RU2015134562A (es)
SG (1) SG192694A1 (es)
TW (2) TW201527322A (es)
UA (1) UA110049C2 (es)
WO (1) WO2012109373A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
AU2011223919B2 (en) 2010-03-02 2015-03-19 Abbvie Inc. Therapeutic DLL4 binding proteins
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP6109952B2 (ja) 2012-11-01 2017-04-05 アッヴィ・インコーポレイテッド 抗ｖｅｇｆ／ｄｌｌ４二重可変ドメイン免疫グロブリンおよびこれらの使用
WO2015084883A2 (en) * 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3341012A4 (en) * 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CN105106490A (zh) * 2015-09-02 2015-12-02 济南舜昊生物科技有限公司 一种治疗小儿髋关节积液的药物及其制备方法
CA3003243A1 (en) * 2015-10-30 2017-05-04 Eli Lilly And Company Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
DK3402530T3 (da) * 2016-01-13 2020-11-23 Genzyme Corp Rekombinante aav-vektorer, der udtrykker knoglebeskyttende gener, herunder has2 og lubricin, som er anvendelige til behandling af osteoarthritis og relaterede ledtilstande hos pattedyr
DK3365368T3 (da) 2016-03-11 2023-06-26 Scholar Rock Inc Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
JP7165410B2 (ja) 2016-08-19 2022-11-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
US20190255152A1 (en) * 2016-10-31 2019-08-22 Kolon Life Science, Inc. Composition for alleviating or treating pain
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
CA3046347A1 (en) 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated Il-1ra cdnas
KR20190098255A (ko) * 2017-01-06 2019-08-21 스칼러 락, 인크. 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
TWI671761B (zh) * 2017-05-01 2019-09-11 臺中榮民總醫院 脊椎關節炎患者疾病活動度電子病歷管理系統
EP3810125A4 (en) * 2018-06-03 2022-02-23 Glycomira Therapeutics, Inc. PROCEDURES TO PREVENT SERIOUS HEALTH EFFECTS AND/OR TISSUE DAMAGE FOLLOWING EXPOSURE TO IONIZING RADIATION AND/OR CHEMOTHERAPY
CN110652502A (zh) * 2018-06-28 2020-01-07 复旦大学 一种靶向治疗类风湿关节炎的药物组合物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286388C2 (ru) * 1988-05-27 2006-10-27 Амген Инк. Ингибитор интерлейкина-1, способ его получения, молекула днк, кодирующая ингибитор интерлейкина-1 и его предшественник
SK288144B6 (sk) * 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
KR20080099355A (ko) * 1999-07-21 2008-11-12 오메로스 코포레이션 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
CN1451043A (zh) * 2000-06-29 2003-10-22 艾博特公司 双特异性抗体及其制备方法和用途
WO2003073982A2 (en) * 2002-02-28 2003-09-12 Eli Lilly And Company Anti-interleukin-1 beta analogs
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
BRPI0506679A (pt) * 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
PL2314623T3 (pl) 2005-06-21 2012-11-30 Xoma Us Llc Przeciwciała wiążące il-1 beta i ich fragmenty
SG2014010029A (en) * 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN103405768A (zh) 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
MX2011007987A (es) 2009-01-29 2011-08-17 Abbott Lab Proteinas de enlace il-1.
TW201116624A (en) 2009-05-01 2011-05-16 Abbott Lab Dual variable domain immunoglobulin and uses thereof
TW201124427A (en) 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
DK2571532T3 (en) * 2010-05-14 2017-08-28 Abbvie Inc IL-1 BINDING PROTEINS
US9234249B2 (en) 2010-07-12 2016-01-12 Gen-Probe Incorporated Compositions and assays to detect swine H1N1 influenza A virus, seasonal H1 influenza A virus and seasonal H3 influenza A virus nucleic acids
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
AU2012340878A1 (en) * 2011-11-21 2014-06-12 Abbvie Inc. IL-1 binding proteins

Also Published As

Publication number Publication date
US8889130B2 (en) 2014-11-18
RU2563830C2 (ru) 2015-09-20
IL227771A0 (en) 2013-09-30
EP2672997A2 (en) 2013-12-18
TW201307389A (zh) 2013-02-16
KR20150080033A (ko) 2015-07-08
TWI531377B (zh) 2016-05-01
CN103596591B (zh) 2016-08-24
MX341578B (es) 2016-08-25
RU2013141211A (ru) 2015-03-20
MX2013009130A (es) 2014-07-09
CA2826564A1 (en) 2012-08-16
RU2015134562A (ru) 2018-12-24
CN105749286A (zh) 2016-07-13
DOP2013000178A (es) 2014-06-30
WO2012109373A3 (en) 2012-11-01
AU2012214449B2 (en) 2016-07-07
JP5918275B2 (ja) 2016-05-18
CO6751274A2 (es) 2013-09-16
BR112013020259A2 (pt) 2018-05-15
CN103596591A (zh) 2014-02-19
TW201527322A (zh) 2015-07-16
NZ614207A (en) 2015-12-24
RU2015134562A3 (es) 2018-12-24
DOP2016000114A (es) 2016-06-15
WO2012109373A2 (en) 2012-08-16
JP2014507434A (ja) 2014-03-27
SG192694A1 (en) 2013-09-30
JP2016106086A (ja) 2016-06-16
AU2012214449A1 (en) 2013-05-02
US20150050238A1 (en) 2015-02-19
AU2016203917A1 (en) 2016-07-07
CL2013002298A1 (es) 2014-08-08
UA110049C2 (uk) 2015-11-10
US20120201781A1 (en) 2012-08-09
KR20130130825A (ko) 2013-12-02
CA2826564C (en) 2018-05-15
EP2672997A4 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112016014830A2 (pt) Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CO6710926A2 (es) Compuestos de n-heteroarilo
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade